Celltrion Healthcare

Remsima SC

Remsima SC

Remsima®SC is the world's first SC formulation of biosimilar infliximab developed by Celltrion. It was approved by the European Medicines Agency(EMA), Korean Ministry of Food and Drug Safety(MFDS) and Health Canada.

• Product Name : Remsima®SC
• INN : Infliximab
• Indications : Rheumatoid Arthritis(RA), Crohn’s disease(CD), Ulcerative Colitis(UC), Ankylosing Spondylitis(AS), Psoriatic Arthritis(PsA), Psoriasis in adult patients
• Protein Type : Monoclonal antibody (mAb)
• Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
• Drug Approval Status : Korea, Europe, Canada